Canyelles, M.; Plaza, M.; Rotllan, N.; Llobet, D.; Julve, J.; Mojal, S.; Diaz-Ricart, M.; Soria, J.M.; Escolà -Gil, J.C.; Tondo, M.;
et al. TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. J. Clin. Med. 2022, 11, 1425.
https://doi.org/10.3390/jcm11051425
AMA Style
Canyelles M, Plaza M, Rotllan N, Llobet D, Julve J, Mojal S, Diaz-Ricart M, Soria JM, Escolà -Gil JC, Tondo M,
et al. TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine. 2022; 11(5):1425.
https://doi.org/10.3390/jcm11051425
Chicago/Turabian Style
Canyelles, Marina, Melania Plaza, Noemà Rotllan, Dolors Llobet, Josep Julve, Sergi Mojal, Maribel Diaz-Ricart, José Manuel Soria, Joan Carles Escolà -Gil, Mireia Tondo,
and et al. 2022. "TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism" Journal of Clinical Medicine 11, no. 5: 1425.
https://doi.org/10.3390/jcm11051425
APA Style
Canyelles, M., Plaza, M., Rotllan, N., Llobet, D., Julve, J., Mojal, S., Diaz-Ricart, M., Soria, J. M., Escolà -Gil, J. C., Tondo, M., Blanco-Vaca, F., & Souto, J. C.
(2022). TMAO and Gut Microbial-Derived Metabolites TML and γBB Are Not Associated with Thrombotic Risk in Patients with Venous Thromboembolism. Journal of Clinical Medicine, 11(5), 1425.
https://doi.org/10.3390/jcm11051425